搜尋結果
2 小時前 · MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adu…
2024年5月31日 · CURSOS, ASESORAMIENTO INDIVIDUALIZADO...ATTE.JUAN CARLOS QUISPE GARCÍA CIEPRO CONSULTORESAVENIDA ALBINA PATIÑO YMARGARITA LAZARTEMÓVIL: 591+ 72730304TELÉFONO...
- 1 分鐘
- Ciepro, consultores
1 天前 · https://ameblo.jp:443/ohara-kuwaoha/entry-12854189610.html - 2024年5月30日 18:47 - ウェブ魚拓
1 天前 · 秉着心问副董事长兼总经理冷春生2024-05-29 16:30:46你好，近期在没有特别消息的情况下，公司股价持续下跌，是公司经营有雷吗？135****66962024-05-28 15:04:591，一季度延迟发货对二季度业绩提升有多大影响？ 2、二季度按新中标条件，预计二季度同比环比发货量提高有多少？
1 小時前 · Dr David N. Cade, MD, Group Chief Medical Officer at Telix, stated, “TLX591 is a radio-ADC with significant potential advantages compared to small molecule radiopharmaceuticals in treating prostate cancer.TLX591 is differentiated by a patient-friendly dosing ...
